Tinea Incognito Imitating Pustular Psoriasis in a Psoriatic Patient Following Immunosuppressive Therapy: Case Report and Narrative Review
Abstract
Tinea incognito is an atypical form of dermatophytosis caused by previous use of topical or systemic immunosuppressive therapy, most often corticosteroids. Modification of the clinical presentation frequently leads to diagnostic delay and misdiagnosis, especially in patients with concomitant chronic inflammatory skin diseases such as psoriasis. We present a narrative review of the literature on tinea incognito in patients with psoriasis during immunosuppressive therapy. We screened 386 abstracts and included 16 comparable case reports focusing on tinea incognito occurring in patients with psoriasis or during antipsoriatic treatment. The review summarizes clinical presentations, diagnostic challenges, and therapeutic approaches reported in the literature. Additionally, we present a clinical case of a 27-year-old man with a long history of plaque psoriasis treated with methotrexate and cyclosporine. The patient developed rapidly progressive skin lesions with pustular features and further deterioration despite systemic antipsoriatic therapy. Initial mycological examinations were negative. Histopathological examination revealed a chronic purulent perifollicular inflammatory process with extension into the subcutaneous tissue. The correct diagnosis was confirmed after a repeat skin biopsy with periodic acid-Schiff and Grocott staining and fungal culture of the skin tissue, which revealed Trichophyton rubrum. The review highlights that clinical features are often nonspecific and…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.